What's Happening?
Eli Lilly has announced the successful results of its ACHIEVE-4 trial, which evaluated the safety and efficacy of its oral GLP-1 agonist, Foundayo, in patients with type 2 diabetes. The trial, involving 2,700 participants, compared Foundayo to insulin
glargine and demonstrated a 57% reduced risk of all-cause death and a 16% lower risk of major adverse cardiovascular events (MACE-4). The study also confirmed no signs of drug-induced liver injury, addressing a key safety concern of the FDA. These findings support the drug's potential approval for type 2 diabetes, following its recent approval for obesity treatment.
Why It's Important?
The results of the ACHIEVE-4 trial are significant as they bolster the safety profile of Foundayo, potentially positioning it as a strong competitor in the oral GLP-1 drug market for diabetes. This could impact the market dynamics, especially against Novo Nordisk's Wegovy, which is currently a leading oral GLP-1 drug. The trial's findings may influence prescribing practices and patient preferences, given the drug's comprehensive health benefits and ease of use. Additionally, the reduced cardiovascular risk associated with Foundayo could make it a preferred option for patients with elevated cardiovascular risk.
What's Next?
Eli Lilly plans to seek a national priority review for Foundayo in the diabetes indication, which could expedite its market entry. The company is also likely to enhance its marketing efforts to compete with Novo Nordisk, emphasizing Foundayo's advantages such as flexible dosing without food restrictions. The competition between these pharmaceutical giants may lead to further innovations and pricing strategies that could benefit patients and healthcare providers.
